history of glp-1 drugs Market Size to Hit USD 132.79 Bn by 2035 Discovery of GLP-1–Based Drugs for
Description
SGLT2 inhibitors are indicated for three conditions: T2DM, chronic kidney disease, and chronic heart failure
Water and HFHS food were available ad libitum throughout the study period
GLP-1 and ERK1/2 pathway Multiple cellular functions benefit from ERK1/2 activation
Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis
